ReviewRegenerative therapy2025
Stem cell therapy for urethra and ureter tissue engineering: A systematic literature review on animal studies.
Review in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic advances in ureteral stricture: lessons from radiation-induced fibrosis to regenerative strategies-a narrative review.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study investigates the optimal stem cells for using in ureter and urethra tissue engineering by systematically reviewing the literature. Scopus, PubMed, and Embase databases were searched up to December 2024 to find original studies investigating ureter and urethra tissue engineering by seeding stem cells on the scaffolds in animal models, which resulted in the identification of 1191 studies. Finally, 26 studies were included. Eighteen and eight studies tried urethra and ureter tissue regeneration, respectively. Adipose-derived stem cells were the most commonly used for tissue engineering of the ureter and urethra, with 14 studies. Bone marrow-derived stem cells were involved in 5 studies, urine-derived in 3, muscle-derived stem/precursor cells in 3, and human amniotic membrane-derived mesenchymal stem cells in 1. Bladder acellular matrix, artery extracellular matrix, and small intestinal submucosa were non-synthetic seeded scaffolds that were used in 10 studies. However, studies used biomaterial and synthetic scaffolds, including Poly (l-lactide-co-caprolactone) nano yarn, Poly-glycolic acid, nanofiber, double-modified sulfated bacterial cellulose, and silk scaffold more frequently. Data demonstrated that adipose-derived, bone marrow-derived, urine-derived, and human amniotic membrane-derived stem cells have the capability of both urothelium and smooth muscle regeneration in urethra reconstruction. Furthermore, seeding bone marrow-derived stem cells can improve collagen and vessel formation. Also, this study showed that the muscle-derived SCs or precursor cells are able to regenerate urethra smooth muscle, but data are limited. Hypoxia precondition, subcutaneous or omental pre-incubation, fibroblast growth factor receptor Ⅱ overexpression, and mechanical extension stimulation were employed as boosting conditions. However, data about ureter tissue engineering are limited. Adipose-derived stem cells were the most frequently employed for ureter tissue regeneration, with appropriate outcomes for both urothelium and smooth muscle regeneration however, other types of stem cells should be more investigated for ureter tissue engineering.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.